title: Breast tumor recurrence following lumpectomy with and without breast irradiation: an overview of recent NSABP findings.
abstract: The latest findings from the NSABP B-06 trial on ipsilateral breast tumor recurrence (IBTR) continue to demonstrate that through 9 years of follow-up more patients treated with radiation remained IBTR free as compared to those receiving no radiation (P less than 0.001), regardless of age, nodal status, or tumor size. There is no significant difference in distant disease-free survival (DDFS) or survival between the two lumpectomy groups despite the highly significant difference in their probability of remaining IBTR free. A recent analysis shows that when a patient is diagnosed with an IBTR, the risk of distant metastatic disease increases, indicating that an IBTR is a marker for, not a cause of, distant metastatic disease. An IBTR indicates a greater risk for distant disease when the primary tumor was removed. Mastectomy or breast irradiation following lumpectomy eliminates or reduces the opportunity for identifying a marker of risk for distant disease, thus emphasizing the importance of an IBTR beyond the need for its removal. Since an IBTR is associated with a relative risk of 3.41 for the development of distant metastatic disease, systemic therapy subsequent to an IBTR should be considered. Evidence presented from recent NSABP studies indicates the value of systemic therapy for lowering the incidence of IBTR following lumpectomy and breast irradiation.
authors.affiliation: NSABP Headquarters, Pittsburgh, PA 15261.
authors.forename: B
authors.initials: B
authors.lastname: Fisher
authors.forename: D L
authors.initials: DL
authors.lastname: Wickerham
authors.forename: M
authors.initials: M
authors.lastname: Deutsch
authors.forename: S
authors.initials: S
authors.lastname: Anderson
authors.forename: C
authors.initials: C
authors.lastname: Redmond
authors.forename: E R
authors.initials: ER
authors.lastname: Fisher
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015994:Incidence; D008197:Lymph Node Excision / Q000592:standards; D015409:Mastectomy, Radical / Q000592:standards; D015412:Mastectomy, Segmental / Q000592:standards*; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000592:standards*; D011960:Receptors, Estrogen / Q000032:analysis; D015996:Survival Rate
chemical_list: D011960:Receptors, Estrogen